Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
6
Neutral
2
Bullish
6
Bearish
6
Neutral
2
Bullish
38
Bearish
0
Neutral
0
Bullish
32
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Parmax Pharma Ltd, established in 1994, focuses on Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations (CMO).
The company initially manufactured antibiotics and speciality chemicals but discontinued business activities for some years before focusing on the current pharmaceutical operations.
Located in Gujarat, Parmax's antibiotic manufacturing plant has an installed capacity of 96 TPA, highlighting its production potential.
The company's historical expertise lies in manufacturing bulk drugs such as Amoxycillin and Ampicillin, indicating solid foundations in the pharmaceutical industry.
Promoted by industry veterans, Parmax Pharma's strategic decisions showed resilience and adaptability in a challenging business landscape.
Pharmaceuticals & Biotechnology
Pharmaceuticals
22 Cr
Low Risk
-5.4
34.3
—
—
59.32
22.60
Sales CAGR
Profit CAGR
ROE
ROCE
Parmax Pharma Ltd (PARMAX) is currently trading at 59.32 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Parmax Pharma Ltd, established in 1994, focuses on Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations (CMO). The company initially manufactured antibiotics and speciality chemicals but discontinued business activities for some years before focusing on the current pharmaceutical operations. Located in Gujarat, Parmax's antibiotic manufacturing plant has an installed capacity of 96 TPA, highlighting its production potential. The company's historical expertise lies in manufacturing bulk drugs such as Amoxycillin and Ampicillin, indicating solid foundations in the pharmaceutical industry. Promoted by industry veterans, Parmax Pharma's strategic decisions showed resilience and adaptability in a challenging business landscape.
Over the past 52 weeks, Parmax Pharma Ltd has traded between a low of ₹22.60 and a high of ₹59.32. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Parmax Pharma Ltd has a market capitalization of approximately 22.19. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Parmax Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -5.35 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 22.19 Cr, Parmax Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Parmax Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Parmax Pharma Ltd is -5.35. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The board approved raising ₹19,28,19,682 through a preferential issue of 31,37,586 equity shares and 21,45,145 convertible warrants at ₹36.50 each.
An open offer has been announced to acquire up to 26% of Parmax Pharma’s expanded voting capital at an offer price of ₹42.80 per share.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
19.40 | 24 Cr | -5.87 | 0.82 | 0.00 | -13.99 | -10.62 | -7.79 | ||
39.00 | 24 Cr | -94.04 | 0.00 | 0.00 | 20.74 | -104.17 | -21.01 | ||
20.00 | 23 Cr | 115.85 | 1.64 | 0.00 | 1.76 | 1.92 | 1.23 | ||
74.70 | 22 Cr | 28.77 | 1.94 | 0.00 | 6.73 | 9.78 | 6.19 | ||
59.32 | 22 Cr | -5.35 | 0.00 | 0.00 | 67.65 | -85.76 | -14.80 | ||
40.00 | 22 Cr | 14.58 | 0.94 | 0.00 | 6.49 | 7.62 | 0.44 | ||
23.20 | 22 Cr | 8.82 | 1.15 | 0.00 | 13.09 | 13.74 | 4.84 | ||
| Median: 7 Co. | — | 39.00 | 22 Cr | 8.82 | 0.94 | 0.00 | 6.73 | 1.92 | 0.44 |
EGM Notice
Parmax Pharma schedules EGM on July 2, 2026 (VC) to approve increase in authorised capital to ₹10 crore, adopt new AOA, and a preferential allotment of 31,37,586 equity shares at ₹36.50 each to specified non‑promoter individuals.
Change of control
Acquirers and PACs entered a Share Purchase Agreement to acquire promoter shares at ₹35 per share and will pursue majority control via preferential allotment, secondary acquisition and an open offer; subject to statutory approvals.
Open Offer
Acquirers Dhiren Chandulal Shah and Sunil Chinubhai Shah (with PACs) announced an open offer to acquire up to 23,46,250 equity shares (26% of expanded voting capital) of Parmax Pharma at ₹42.80/share (total consideration up to ₹10.04 crore).
Open Offer
Acquirers Dhiren C. Shah and Sunil C. Shah, with PACs, propose an open offer to acquire up to 23,46,250 equity shares (26% of expanded voting capital) of Parmax Pharma at ₹42.80/share (total up to ₹10,04,19,500), subject to approvals.
Preferential Issue
Board approved increase in authorised capital to ₹10.00 Cr, adoption of new AOA, and a preferential issue to raise up to ₹19.28 Cr (31,37,586 equity shares and 21,45,145 warrants at ₹36.50 each); ID committee recommended; EGM on Jul 2, 2026; acquirers aim for majority control.
Preferential Issue
Board approved increase in authorised capital to Rs.10.00 crore, adoption of new AOA and a preferential issue of 31,37,586 equity shares and 21,45,145 warrants to raise up to ₹19.28 crore; proposed acquirers seek control; EGM on Jul 2, 2026.
